Corning launches Elplasia 12K flask to support spheroid demand in therapy, cancer research

By The Science Advisory Board staff writers

October 18, 2022 -- Multinational technology company Corning has announced an addition to its 3D cell culture portfolio that provides a new solution to support spheroid culture, which is commonly used in advanced therapy development and cancer research.

The Corning Elplasia 12K flask designed in a convenient format and is compatible with many tumor, normal, and primary cell types often used in 3D cell culture. It features a unique microcavity geometry that enables easy spheroid formation, culture, treatment, assessment, and harvest, with approximately 12,000 spheroids of uniform size and shape per flask, generating 125 times more yield than conventional 96-well spheroid plates.

"This new tool will allow for uniform and highly reproducible formation of spheroids at the volumes essential to further research in areas like cell therapy research, 3D tissue engineering, and extracellular vesicle and biomolecule production," said John Tobin, vice president and general manager at Corning Life Sciences, in a statement.

Corning's Elplasia 12K flask is a plug-and-play solution that is ready-to-use, sterile, and requires no specialty reagents to support the bulk production of spheroids, according to the company. It also features Corning's Ultra Low Attachment surface, an optically clear flask bottom for easy spheroid visualization and gas permeable polystyrene film microcavity substrate to support long-term 3D cell culture.

As demand for spheroids continues to increase as research and technology in drug screening, cancer research, and advanced therapies rapidly evolves, the Corning Elplasia 12K flask will be vital to advancing the effectiveness of 3D spheroids in many areas of research, the company said.


Copyright © 2022 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.